Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
NCT00539162 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaire
Study Locations (11)
Texas
- The University of Texas at Austin — Austin
- University of Texas (UT) Southwestern Medical Center — Dallas
- University of Texas MD Anderson Cancer Center — Houston
- Women's Hospital of Texas, Obstetrics and Gynecology Associates (OGA) — Houston
- UT Health Science Center San Antonio — San Antonio
Florida
- Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine — Miami
Iowa
- John Stoddard Cancer Center — Des Moines
New Jersey
- Carol G. Simon Cancer Center / Atlantic Health — Morristown
New York
- University of Rochester Medical Center — Rochester
Oklahoma
- University of Oklahoma Health Sciences Center — Oklahoma City
Rhode Island
- Women's and Infant's Hospital — Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2001-07-02 |
| Est. Completion | 2028-11-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539162
The ClinicalTrials.gov registry entry for NCT00539162 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 8,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,992 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention — of which Questionnaire is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00539162 reports 11 study locations spanning 7 distinct geographic areas — top geographies include Texas, Florida, Iowa. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00539162 about?
NCT00539162 is a clinical study titled "Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women". The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk.
What is the current status of trial NCT00539162?
This trial is currently recruiting. It is a NA study. The enrollment target is 8,000 participants. The study started on 2001-07-02. Estimated completion is 2028-11-30.
What conditions does trial NCT00539162 study?
This clinical trial studies the following conditions: Ovarian Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00539162?
The interventions under investigation include: Questionnaire (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00539162?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,992 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00539162 being conducted?
This trial has 11 study locations across Florida, Iowa, New Jersey, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.